EL7.AI
StocksMedium•30 October 2026•
2 min read

CareDx Posts $139 Million in Revenue, Beats Estimates and Raises 2026 Forecast

Key Facts

1Third-quarter revenue was $139 million, up 39% year over year from $100 million in the third quarter of 2025.
2Adjusted earnings per share were $0.70, versus analysts' estimate of $0.26, and revenue beat their estimate of $121.95 million.
3The company raised its 2026 revenue forecast to $520–530 million and adjusted EBITDA forecast to $90–100 million.
4The stock rose 15.07% after hours to $82.30 on October 29, 2026, after the session closed at $71.52.

CareDx said revenue for the third quarter ended September 30, 2026, reached $139 million, up 39% year over year. Revenue was $100 million in the same period of 2025, according to the company's statement via Business Wire. The result topped analysts' estimate of $121.95 million, according to Investing.com data. The company also reported adjusted earnings per share of $0.70, versus an estimate of $0.26. The company raised its annual forecast, accompanying its beats on market estimates for revenue and earnings.

Chief Executive John Hanna attributed the results to "another quarter of strong execution" and said the company continued to grow its transplant business and made progress expanding specialty oncology. He added that the company advanced its product pipeline and clinical evidence, including in cell therapy. The company said it was facilitating adoption of and access to its solutions, amid growing clinical interest in expanding the use of molecular information in patient-care decisions. In specialty oncology, the acquisition of Navier added revenue to the company, while CareDx also moved "NavDx" onto its billing platform.

CareDx expects revenue of between $520 million and $530 million in fiscal 2026, and adjusted EBITDA of between $90 million and $100 million. For the fourth quarter, the company set a revenue range of $131 million to $141 million and adjusted EBITDA of $16 million to $26 million. It also expects total test volume in the quarter to range between 76,000 and 80,000 tests. The company's stock, which trades under the ticker CDNA, closed at $71.52 on October 29, 2026. After hours, the stock rose 15.07% to $82.30, according to an Investing.com report.

On upcoming products, the company said "AlloHeme" remains on track to complete readiness before the end of 2026, with commercial launch targeted for the first quarter of 2027. CareDx also aims to complete readiness for "HistoMap Kidney" before the end of 2026. The company plans to expand its availability during 2027. These timelines put the company's products among the developments markets will track after the annual forecast update and fourth-quarter guidance. The stated launch and availability dates remain future targets announced by the company.

Open on chart